This study is a Phase 1 clinical trial to test the safety and ability of two new vaccines, DV201P-RNA and DV202B1-RNA, to produce certain antibodies that fight HIV. The vaccines use special molecules called mRNA (messenger RNA) inside tiny fat particles to help the body make parts of the HIV virus that trigger an immune response. These vaccines don't contain the HIV virus itself, so they can't cause HIV.

Key Points:

• Participants must be healthy adults aged 18-55 without HIV.
• The trial involves multiple clinic visits for follow-up checks.
• Participants should not be pregnant or breastfeeding and must use effective birth control during the study.

People with certain health issues, like diabetes, asthma, or a history of serious allergic reactions, may not be eligible. The study aims to ensure participants' safety while exploring how well these vaccines work in creating a protective immune response against HIV.